Advertisement
UK markets open in 1 hour 38 minutes

  • NIKKEI 225

    38,648.63
    +15.61 (+0.04%)
     

  • HANG SENG

    17,992.45
    -342.87 (-1.87%)
     

  • CRUDE OIL

    82.34
    +0.17 (+0.21%)
     

  • GOLD FUTURES

    2,375.90
    +6.90 (+0.29%)
     

  • DOW

    39,134.76
    +299.90 (+0.77%)
     

  • Bitcoin GBP

    50,944.26
    -593.41 (-1.15%)
     

  • CMC Crypto 200

    1,354.63
    -28.04 (-2.03%)
     

  • NASDAQ Composite

    17,721.59
    -140.64 (-0.79%)
     

  • UK FTSE All Share

    4,508.44
    +35.07 (+0.78%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

Karyopharm to Participate at the Jefferies Global Healthcare Conference

PR Newswire
·2-min read

NEWTON, Mass., May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.

(PRNewsfoto/Karyopharm Therapeutics Inc.)
(PRNewsfoto/Karyopharm Therapeutics Inc.)

A live webcast of the event, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay following the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

ADVERTISEMENT

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html

SOURCE Karyopharm Therapeutics Inc.